Caremark, Optum Say FTC Insulin Case Gets PBMs All Wrong
By Bryan Koenig · October 16, 2024, 5:23 PM EDT
Caremark Rx, Express Scripts and OptumRx continue to attack the Federal Trade Commission's in-house case accusing the country's three largest pharmacy benefit managers of artificially inflating insulin prices by relying on...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login